Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

EMA Recommends Granting a Marketing Authorisation for Ensartinib
Дата публикации: 09-10-2026 07:00:00

It is intended for the treatment of adult patients with ALK-positive, advanced NSCLC

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1EMA recommends granting a marketing authorisation for relacorilant09.2502-10-2026
2EMA recommends extension of indications for pirtobrutinib08.8625-09-2026
3GSK’227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA 016.4710-12-2025
4Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease (COPD)06.105-01-2026
5FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer014.7923-09-2026
6Exdensur (depemokimab) approved in China for the treatment of severe asthma 06.7730-03-2026
7A new treatment has been approved for extensive-stage small cell lung cancer07.6624-09-2026
8ГК «ХимРар» запускает программу раннего доступа к терапии РМЖ инновационным препаратом биреоциклиб09.430-09-2026
9Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS08.7130-09-2026
10No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC016.4124-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.61. Источник: www.esmo.org.